Matthew Ronsheim
Corporate Officer/Principal at ENTASIS THERAPEUTICS HOLDINGS INC.
Net worth: 607 245 $ as of 30/04/2024
Matthew Ronsheim active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 | - |
Career history of Matthew Ronsheim
Former positions of Matthew Ronsheim
| Companies | Position | Start | End |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 01/06/2016 | 01/08/2019 |
| Corporate Officer/Principal | 01/06/2016 | 01/08/2019 |
Training of Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Matthew Ronsheim
- Experience
